Abstract. Epigenetic changes as well as genetic changes are mechanisms of tumorigenesis. We aimed to identify novel genes that are silenced by DNA hypermethylation in hepatocellular carcinoma (HCC). We screened for genes with promoter DNA hypermethylation using a genome-wide methylation microarray analysis in primary HCC (the discovery set). The microarray analysis revealed that there were 2,670 CpG sites that significantly differed in regards to the methylation level between the tumor and non-tumor liver tissues; 875 were significantly hypermethylated and 1,795 were significantly hypomethylated in the HCC tumors compared to the non-tumor tissues. Further analyses using methylation-specific PCR, combined with expression analysis, in the validation set of primary HCC showed that, in addition to three known tumorsuppressor genes (APC, CDKN2A, and GSTP1), eight genes (AKR1B1, GRASP, MAP9, NXPE3, RSPH9, SPINT2, STEAP4, and ZNF154) were significantly hypermethylated and downregulated in the HCC tumors compared to the non-tumor liver tissues. Our results suggest that epigenetic silencing of these genes may be associated with HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide (1) . It is estimated to cause approximately half a million deaths annually. Several risk factors for HCC have been reported, including infection with hepatitis B and hepatitis C viruses, dietary intake of afratoxin, and alcohol consumption. However, the molecular pathogenesis of HCC is not fully understood.
Epigenetic changes are the mechanisms of tumorigenesis as well as genetic changes such as chromosomal alternations, gene amplifications, deletions, and mutations. DNA methylation of CpG islands within the promoter regions of tumor-suppressor genes is known to inhibit transcriptional initiation, and thereby silence these genes. Tumor-suppressor genes that are frequently methylated in HCC include APC (2), CDKN2A (3), RASSF1A (4), and GSTP1 (5) . Aberrant DNA methylation of various tumor-suppressor genes is suggested to be correlates with biological features and clinical outcome of HCC (6, 7) .
In the present study, we aimed to identify novel genes that are silenced by DNA hypermethylation in HCC. We screened for genes with promoter DNA hypermethylation using a genome-wide methylation microarray analysis in primary HCC tumors by comparison with their non-tumor tissue counterparts. Further methylation analyses, combined with expression analyses, revealed novel genes that were downregulated by aberrant promoter hypermethylation in HCC.
Materials and methods

Primary tumors and cell lines.
Paired tumor and non-tumor tissues were obtained from HCC patients who underwent surgery at the Hospital of Tokyo Medical and Dental University. All specimens were immediately frozen in liquid nitrogen and were stored at -80˚C until required. Table I summarizes the clinical characteristics of a total of 47 patients (20 in the discovery set and 27 in the validation set) in the present study. The protocol of this study was approved by the ethics committees and conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from each patient.
Three HCC cell lines, SNU449, Li7 and HLF, were examined. All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum.
DNA extraction and bisulfite modification. Genomic DNA was isolated using the Puregene DNA isolation kit (Gentra, Minneapolis, MN, USA). Bisulfite modification of DNA was performed using an EZ DNA Methylation kit (Zymo Research, Irvine, CA, USA).
Illumina HumanMethylation27
BeadChip. Genome-wide DNA methylation was analyzed by the HumanMethylation27 BeadChip (Illumina, San Diego, CA, USA), according to the instructions from the manufacturer. This Illumina BeadChip interrogates 27,578 CpG sites, which were selected predominantly from the promoter regions of an annotated 14,475 genes. Data were analyzed using Illumina GenomeStudio software. Methylation values are expressed as a β-value (between 0 and 1) for each CpG site, representing a continuous measurement from 0 (completely unmethylated) to 1 (completely methylated).
Differential methylation was assessed by comparing the mean methylation level (β-value) of HCC tumor tissues with the mean β-value of non-tumor liver tissues. Selection of significantly differentially methylated loci was based on i) a β-value difference [delta (Δ) β] of at least 0.15 between HCC tumor and non-tumor samples and ii) a p-value of <0.01 as determined by paired t-test with false-discovery rate (FDR) correction for multiple comparisons, based on the Benjamini and Hochberg procedure (8) .
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Total RNA was obtained using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). qRT-PCR experiments were performed with the LightCycler system using FastStart DNA Master Plus SYBR Green I (Roche Diagnostics, Penzberg, Germany), as previously described (9) . The primers used are listed in Table II . The endogenous control for mRNA was ACTB.
Methylation-specific PCR (MSP)
. MSP was performed, as previously described (10) . Briefly, genomic DNA was treated with sodium bisulfite and subjected to PCR using specific primer sets (Table II) .
Combined bisulfite and restriction analysis (COBRA).
COBRA was performed, as previously described (10) . Briefly, genomic DNA was treated with sodium bisulfite and subjected to PCR using primers (Table ΙΙ) designed to amplify a region from -97 to +239 bp relative to the transcription start site of STEAP4. The PCR products were digested with HpyCH4IV, which recognizes sequences unique to the methylated alleles, but cannot recognize unmethylated alleles, and the digested products were electrophoresed on 3% agarose gels and stained with ethidium bromide. Methylation levels were calculated as the ratio of the gray scale value of the methylated band to that of the combined methylated and unmethylated bands. The gray scale value was obtained by scanning the gel with Adobe Photoshop CS3 Extended software (Adobe Systems Incorporated, San jose, CA, USA). Methylated and unmethylated bisulfite-converted control DNA (EpiTect control DNA set; Qiagen, Tokyo, japan) served as controls for methylated and unmethylated DNA, respectively, in MSP and COBRA.
Drug treatment. Cells were treated with 1 or 5 µM of 5-aza-2'-deoxycytidine (5-aza-dC; Sigma-Aldrich, St. Louis, MO, USA) for 4 days or 50 ng/ml of trichostatin A (TSA; Wako, Osaka, japan) for 1 day. In assessing drug synergy, cells were cultured in the presence of 1 or 5 µM of 5-aza-dC for 4 days, and were then treated for an additional 24 h with 50 ng/ml of TSA.
Immunohistochemistry. The HCC tissue microarray (US Biomax, Rockville, MD, USA) was analyzed for STEAP4 protein expression. Anti-STEAP4 polyclonal antibody (Proteintech, Chicago, IL, USA) was used at a dilution of 1:50. Immunostaining of STEAP4 was carried out with the EnVision+ system (Dako, Tokyo, Japan).
Statistical analyses.
Fisher's exact probability test, paired t-test, and Wilcoxon signed-rank test were performed using SPSS 15.0 software (SPSS, Inc., Chicago, IL, USA). P-values of <0.05 were considered significant. KEGG pathway analysis (11) was performed to identify biological pathways significantly enriched for differentially methylated genes using the functional annotation tool of the Database for Annotation Visualization and Integrated Values are number or mean ± SD. Where no other unit is specified, values refer to the number of patients.
a According to the staging system of the Liver Cancer Study Group of japan.
Discovery (DAVID) version 6.7 (12, 13) . P-values were calculated using a modified Fisher's exact test (EASE score).
Results
Genome-wide DNA methylation profiling of primary HCC.
To identify genes that are silenced by DNA hypermethylation in HCC, we compared DNA methylation profiles between paired tumor and non-tumor tissues from 20 patients with primary HCC (the discovery set) using Illumina HumanMethylation27 BeadChip. The array data have been submitted to NCBI GEO under accession number (GSE73003). The strategy of the present study is shown as a flowchart in Fig. 1 . Overall, the average methylation level was slightly but significantly higher in the HCC tumors than the matched non-tumor liver tissues (median β-value of 0.093 and 0.091 in HCC tumors and non-tumor liver tissues, respectively) ( Fig. 2A ). There were 2,670 CpG sites that significantly differed in regards to the methylation level between the tumor and non-tumor tissues (Δβ >0.15 and P<0.01, see Materials and methods). Of these 2,670 CpG sites, 875 were significantly hypermethylated and 1,795 were significantly hypomethylated in the HCC tumors compared to the non-tumor liver tissues. Fig. 2B shows a heatmap of 2,670 significantly differentially methylated CpG sites between the HCC tumors and non-tumor liver tissues. Good separation of HCC tumors and non-tumor liver tissues was observed. While the HCC tumors showed a variation in methylation profiles, the non-tumor liver tissues did not.
KEGG pathway analysis was performed to identify biological pathways significantly enriched for the 695 hypermethylated genes corresponding to 875 CpG sites that were hypermethylated in the HCC tumors. Four KEGG pathways, including neuroactive ligand-receptor interaction, focal adhesion, vascular smooth muscle contraction, and systemic lupus erythematosus, were significantly enriched for hypermethylated genes (Table III) .
Selection and validation of candidate methylated genes. We focused on further examination for the top 30 most hypermethylated genes in the HCC tumors compared to the non-tumor liver tissues (Table IV) . The list of 30 genes included three known tumor-suppressor genes, APC (adenomatous polyposis 
COBRA, combined bisulfite and restriction analysis; M, methylation-specific primer; U, unmethylation-specific primer. coli), CDKN2A (cyclin-dependent kinase inhibitor 2A) and GSTP1 (glutathione S-transferase pi 1), which are known to be silenced by DNA hypermethylation in HCC (14, 15) , supporting the appropriateness of our methodology. We examined whether the remaining 27 genes were silenced by DNA hepermethylation in the paired tumor and non-tumor tissues from an additional 27 patients with primary HCC (the validation set) using MSP and qRT-PCR. Of the 27 genes, eight genes (AKR1B1, GRASP, MAP9, NXPE3, RSPH9, SPINT2, STEAP4, and ZNF154) were significantly hypermethylated and downregulated in the HCC tumors compared to the non-tumor liver tissues ( Fig. 3 and Table V) . Therefore, these eight genes were identified and validated to be methylated genes in HCC. Epigenetic silencing of STEAP4. As an example, we further assessed the methylation status of STEAP4, as little is known about the association of STEAP4 with HCC. Using the Methyl Primer Express software ver.1.0 (Applied Biosystems, Foster City, CA, USA), a CpG island was found around the transcription start site of STEAP4 (Fig. 4A) . To confirm the methylation status of STEAP4, we quantified methylation levels of STEAP4 in the paired tumor and non-tumor tissues from 27 patients with primary HCC (the validation set) using COBRA (Fig. 4B) . The level of methylation of STEAP4 was significantly higher in 25 (93%) of the 27 HCC tumors, compared to their non-tumor tissue counterparts (Wilcoxon signed-rank test, P<0.001) (Fig. 4C) .
To confirm the silencing of STEAP4 in the HCC tumors, we compared the expression of the STEAP4 protein using immunohistochemistry on tissue microarrays. Representative images are shown in Fig. 4D . Whereas the STEAP4 protein was expressed in all of the 30 non-tumor liver tissues, it was expressed in 26 of the 40 HCC tumors (Fisher's exact probability test, P<0.001).
We then assessed the effect of demethylation on the expression of STEAP4. Three HCC cell lines (SNU449, Li7, and HLF) that lack STEAP4 expression were treated with 5-aza-dC, a methyltransferase inhibitor, and expression levels of STEAP4 mRNA were assayed with qRT-PCR. Expression of STEAP4 was restored with 5-aza-dC treatment in a dosedependent manner in all three HCC cells (Fig. 4E) , suggesting that aberrant DNA methylation suppressed the expression of STEAP4. Additionally, it was observed that treatment with a histone deacetylase inhibitor, TSA, enhanced the expression of STEAP4 by 5-aza-dC in all three cell lines (Fig. 4E ). This finding suggests that histone deacetylation may also contribute to the transcriptional repression of STEAP4.
Discussion
In the present study, AKR1B1, GRASP, MAP9, NXPE3, RSPH9, SPINT2, STEAP4 and ZNF154 were identified as genes that are silenced by DNA hypermethylation in HCC. Except for GRASP and SPINT2, to our knowledge, this is the first study to describe the hypermethylation of AKR1B1, MAP9, NXPE3, RSPH9, STEAP4 and ZNF154 in HCC and the relevance of these genes with HCC. Our methodology appears to be appropriate, since APC, CDKN2A and GSTP1, which are known methylated genes in HCC, were also identified by our approach.
GRASP [GRP1 (general receptor for phosphoinositides 1)-associated scaffold protein; also known as Tamalin] encodes a protein that functions as a molecular scaffold and contains several putative protein-protein interaction motifs. It regulates the membrane trafficking pathway (16, 17) . Although a recent study showed the hypermethylation of GRASP in hepatitis B-virus related HCC (18) , its functional relevance for the development of HCC remains unknown.
SPINT2 (serine peptidase inhibitor, Kunitz type, 2) encodes Kunitz-type serine protease inhibitor called hepatocyte growth factor activator inhibitor type 2 (HAI-2). Recent studies have suggested that SPINT2 is a candidate tumor-suppressor gene that is frequently hypermethylated and underexpressed in human cancers, including hepatocellular carcinomas (19, 20) , gastric carcinomas (21), ovarian cancer (22) , cervical cancer (23), renal cell carcinoma (24) , and esophageal squamous cell carcinoma (25) . Studies showed that ectopic expression of SPINT2 significantly inhibited cell migration and invasiveness of HCC cells in vitro and suppressed tumorigenicity in vivo (20) .
AKR1B1 (aldo-keto reductase family 1, member B1) encodes aldose reductase, which participates in glucose metabolism and osmoregulation and is believed to play a protective role against toxic aldehydes derived from lipid peroxidation and steroidogenesis. AKR1B1 is mainly expressed in the adrenal grand and its expression is decreased in adrenocortical cancer (26) . STEAP4 (STEAP family member 4), also known as STAMP2, is a member of the six transmembrane epithelial antigen of prostate (STEAP) family and functions as a metalloreductase. STEAP4 is involved in adipocyte development and metabolism, and it is essential for maintenance of systemic metabolic homeostasis (27) . Studies suggest that STEAP4 may contribute to normal physiology of the prostate as well as prostate cancer progression. STEAP4 was reported to be overexpressed in primary prostate cancer (28) , whereas it was also reported that the STEAP4 promoter region is methylated in androgen-independent prostate cancer cells, but not in androgen-dependent prostate cancer cells (29) .
ZNF154 (zinc finger protein 154) encodes a protein that belongs to the zinc finger Kruppel family of transcriptional regulators. Although the function of ZNF154 is unknown, hypermethylation of this gene was recently reported in bladder cancer (30) and ovarian cancer (31) .
MAP9 (microtubule-associated protein 9; also known as ASAP) is a microtubule-associated protein required for spindle function, mitotic progression, and cytokinesis (32) . Expression of MAP9 is downregulated in colorectal cancer compared to normal tissues (33) . RSPH9 (radial spoke head 9 homolog) encodes a protein thought to be a component of the radial spoke head in motile cilia and flagella. Mutations in this gene have been found in patients with primary ciliary dyskinesia (34) . However, the relevance of RSPH9 with cancer has not been reported. The function of NXPE3 (neurexophilin and PC-esterase domain family, member 3) is unknown.
Of these eight genes, we further examine the methylation status of STEAP4 using a variety of methods, including COBRA and the treatment with a methyltransferase inhibitor and a histone deacetylase inhibitor. We confirmed the hypermethylation of the promoter region of STEAP4 in HCC. Moreover, qRT-PCR and immunohistochemistry showed that the expression of STEAP4 was downregulated at the mRNA and protein levels in HCC. These combined results suggest that the silencing of STEAP4 by aberrant promoter hypermethylation may be associated with the development and progression of HCC. We are now going to study the relationship between the reduced expression of STEAP4 in HCC tumors and clinicopathological features with a larger number of samples. It is also required to study the functional role of STEAP4 in hepatocarcinogenesis.
Our pathway analysis suggested that hypermethylated genes may be involved in the pathways of neuroactive ligand-receptor interaction, focal adhesion, vascular smooth muscle contraction, and systemic lupus erythematosus in HCC. However, the relevance of hypermethylated genes with these pathways is largely unknown.
Functional studies are needed to clarify the roles of hypermethylated genes that were identified in the present study in the development and progression of HCC, as they could be useful markers for the diagnosis or be targets for the therapy of HCCs.
